BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
BioAtla's EPS for the twelve months ending Jun 30, 2026 was -$25.63. For fiscal 2025 it was -$50.50. The highest annual figure on record is -$50.50 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.50 | – |
| FY2024 | Dec 31, 2024 | -$72.00 | – |
| FY2023 | Dec 31, 2023 | -$129.00 | – |
| FY2022 | Dec 31, 2022 | -$137.00 | – |
| FY2021 | Dec 31, 2021 | -$138.00 | – |
| FY2020 | Dec 31, 2020 | -$159.50 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.27 | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.22 | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.18 | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.50 | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.99 | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.16 | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.99 | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.00 | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.00 | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.00 | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.05 | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.00 | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.50 | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.00 | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.70 | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.50 | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.50 | – |
| Q1 FY2022 | Mar 31, 2022 | -$32.50 | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.62 | – |
| Q3 FY2021 | Sep 30, 2021 | -$34.00 | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.00 | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.50 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?